newsfilter
← Latest News
Business Wire·

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2